FY2027 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Lifted by Roth Capital

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at Roth Capital raised their FY2027 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Wednesday, May 8th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $1.98 per share for the year, up from their prior forecast of $1.89. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.65) per share.

Other research analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. William Blair reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. Finally, Maxim Group lifted their price objective on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, April 2nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $19.50.

Zevra Therapeutics Stock Down 2.5 %

Shares of ZVRA traded down $0.13 during midday trading on Thursday, hitting $5.03. The company had a trading volume of 190,159 shares, compared to its average volume of 243,756. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $7.28. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. The stock has a market cap of $218.45 million, a price-to-earnings ratio of -4.00 and a beta of 1.87. The company's 50 day moving average price is $5.36 and its 200 day moving average price is $5.38.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.20). The business had revenue of $13.22 million during the quarter, compared to analyst estimates of $13.35 million. Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ZVRA. Janney Montgomery Scott LLC acquired a new position in shares of Zevra Therapeutics during the third quarter worth about $3,250,000. Retirement Planning Co of New England Inc. acquired a new stake in Zevra Therapeutics during the 3rd quarter valued at $1,674,000. Armistice Capital LLC bought a new position in shares of Zevra Therapeutics in the fourth quarter valued at about $1,755,000. Mystic Asset Management Inc. acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $980,000. Finally, Bank of New York Mellon Corp acquired a new stake in Zevra Therapeutics during the third quarter worth approximately $977,000. Institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.